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Background and purpose — Currently, no clear evidence exists 
on the pattern of use of antithrombotics at admission in hip frac-
ture patients and how this has changed over time. We investigated 
temporal trends in—and factors associated with—the use of anti-
thrombotics in patients admitted with a fractured hip. 
Patients and methods — This was a population-based cohort 
study including all patients aged 18 years or above who were 
admitted with a hip fracture in Denmark from 1996 to 2012. The 
Danish national registries were used to collect information on 
medication use, vital status, and comorbidity.
Results — From 1996 to 2012, the proportion of patients using 
antithrombotics in general increased by a factor of 2.3 from 19% 
to 43% (p < 0.001). More specifi cally, the use of anticoagulants 
increased by a factor of 6.8 and the use of antiplatelets increased 
by a factor of 2.1. When we adjusted for possible confounders, 
the use of antithrombotics still increased for every calendar year 
(relative risk (RR) = 1.03, CI: 1.03–1.04; p < 0.001). Age, sex, and 
Charlson comorbidity index were all associated with the use of 
antithrombotics (all p < 0.001). 
Interpretation — The proportion of hip fracture patients 
using antithrombotics at admission has increased substantially 
in Denmark over the last 2 decades. This highlights the need for 
evidence-based guidelines on how to handle patients using anti-
thrombotics to ensure safe surgery and to avoid surgical delay.
■
Patients admitted with a fractured hip often have several 
comorbidities that can affect the perioperative period, and they 
often have poor outcomes (Abrahamsen et al. 2009, Baker et 
al. 2014). Current evidence from non-randomized studies sug-
gests that surgical delay is associated with increased mortality 
in these patients (Daugaard et al. 2012, Nyholm et al. 2015). 
There is therefore a strong focus on minimizing the time 
from admission to surgery. One of the factors that can lead 
to surgical delay is the use of antithrombotics at admission, 
due to the risk of bleeding complications. Warfarin and the 
antiplatelet drug clopidogrel have received special attention 
regarding safe surgery in hip fracture patients (Al-Rashid and 
Parker 2005, Ahmed et al. 2014, Gleason and Friedman 2014, 
Gleason et al. 2014, Doleman and Moppett 2015). In addition 
to balancing the risk of bleeding against early surgery, it is 
also important to consider the risk of thromboembolism when 
discontinuing antithrombotic therapy (Gleason and Friedman 
2014).
During the last 2 decades, several new antithrombotics have 
been marketed for indications such as atrial fi brillation, and for 
prevention of venous thromboembolism. In addition, there has 
been a trend towards more aggressive treatment and preven-
tion of thromboembolic events—as, for example, associated 
with atrial fi brillation—and a corresponding increase in the 
use of antithrombotics (Karve et al. 2012, Shroff et al. 2014). 
It is believed that the use of antithrombotics on admission 
is becoming increasingly common in patients who have been 
admitted with a fractured hip. However, as far as we know, 
there have been no studies investigating the pattern of use of 
antithrombotics in these patients and how this has changed 
over time. This information would be useful in order to esti-
mate the size of the problem and thereby highlight the need for 
evidence-based guidelines on the matter.
The main aim of this study was to determine the temporal 
trends in the use of antithrombotics for hip fracture patients at 
admission, using data from national registries. Secondly, we 
wanted to investigate factors associated with the use of anti-
thrombotics and to compare the trends observed in hip frac-
ture patients with those seen in the background population.






























Acta Orthopaedica 2016; 87 (4): 368–373 369
Patients and methods
Study population
Using the Danish National Patient Registry (DNPR), we iden-
tifi ed all patients aged 18 years or more who were admitted 
with a fractured hip (ICD-10 codes DS720 (femoral neck), 
DS721 (pertrochanteric), and DS722 (subtrochanteric)) 
in Denmark during the period from the January 1, 1996 to 
December 31, 2012. Patients who appeared twice due to a con-
tralateral fracture or to subsequent hip fractures were included 
with the index fracture only. 154,047 patients were eligible for 
inclusion and composed the study cohort.
National patient registries—outcome and covariates
All Danish citizens are registered in the Danish Civil Registra-
tion System (CRS) using a unique 10-digit civil registration 
number (CRN). The unique CRN makes it possible to retrieve 
information on individuals from a variety of national regis-
tries. The use of the CRN in all public records enables almost 
complete follow-up and traceability, and it is possible to 
extract data on birth date and sex from the number (Schmidt et 
al. 2014). Demographic information on people living legally 
in Denmark such as vital status, emigration etc., is available 
from the CRS.
The DNPR contains information on all somatic hospital 
admissions dating back to 1977, and, since 1995, also psy-
chiatric admissions and outpatient visits (Lynge et al. 2011). 
In the DNPR, every hospital visit is registered with a set of 
data that includes a single primary discharge diagnosis or an 
unlimited amount of secondary diagnostic codes. This clas-
sifi cation is done using International Disease Classifi cation 
(ICD) codes. Data from the DNPR were used to defi ne the 
study cohort of all hip fracture patients in Denmark from 1996 
to 2012, and to retrieve data on comorbidities for the patients 
included—dating back to 1995. This was done in the form of 
the Charlson comorbidity index (CCI), which was coded based 
on the method described by Quan et al. (2005). In addition, 
we included information on the following individual groups 
of comorbidities, based on a previous diagnosis of the ICD-10 
codes indicated: atrial fi brillation/fl utter (I48), ischemic heart 
disease (I20–25), pulmonary embolism (I26), stroke/TCI 
(G458–459, I63–64), arterial thromboembolism (I74), deep 
vein thrombosis (I801–803, I808–809, I821-823, I828–829), 
valvular disease (I05–08, I091, I098, I34–39, Z952–954), and 
conditions with artifi cial heart valve (Z952–954).
Similarly to the DNPR, all prescription drugs sold in Den-
mark are registered in the Danish National Prescription Data-
base (DNPB) using the CRN. The database covers the use of 
all prescription pharmaceuticals used outside of hospitals, 
including use at, for example, nursing homes. Data collection 
goes back to 1994 and loss to follow-up is unlikely (Kilde-
moes et al. 2011). Data available from the DNPB include date, 
anatomical therapeutic chemical (ATC) codes, dosage etc. We 
defi ned use of a certain drug as there having been at least 2 
redeemed prescriptions for the individual drug within the year 
preceding the hip fracture. 
Anticoagulants were included in the form of vitamin K 
antagonists (ATC code B01AA) and new oral anticoagulants 
(NOAC) (ATC code B01AE07 (Dabigatran) and B01AF (Riva-
roxaban and Apixaban)). Antiplatelet drugs were included 
in the form of low-dose acetylsalicylic acid (ATC code 
B01AC06), clopidogrel (ATC code B01AC04), dipyridam-
ole (ATC code B01AC07), prasugrel (ATC code B01AC22), 
ticagrelor (ATC code B01AC24), and combination drugs 
((ATC code B01AC30 (Asasantin)). Use of antithrombotics 
was defi ned as use of any of the above-mentioned anticoagu-
lants or antiplatelet drugs. Data on non-oral antithrombotics 
such as heparins were not included. The primary outcome was 
the proportion of users of the individual antithrombotics for 
each of the years from 1996 to 2012.
To obtain information on the use of antithrombotics in the 
general Danish population for comparison, we used publicly 
available data on use of prescription medications and demo-
graphics of the Danish population. Statens Serum Institut meta-
data on the use of prescription medication in Denmark is avail-
able online at www.medstat.dk (Statens Serum Institut). The 
data are based on the DNPB, and drugs are listed according to 
ATC codes. Data on medication use in different age groups and 
according to sex are available for each year since 1999. Sub-
jects are registered if they redeemed at least 1 prescription in 
the year in question. The output can be given as total number of 
patients who redeemed a prescription for the drug in question 
during a particular year. As the data are aggregated, it is not 
possible to deduce whether the same person uses one or more 
antithrombotics. Thus, it is not possible to add the number of 
individuals from different ATC codes.
To calculate the proportion of users in the general popula-
tion, we also used information on the number of people living 
in Denmark on January 1 of each year in different age groups 
and by gender. This information is publicly available through 
Statistics Denmark (Statistics Denmark). An indication of the 
total number of people aged 18 years or more living in Den-
mark is given in Table 4.
Statistics
For baseline characteristics, continuous variables were com-
pared using Student t-tests for normally distributed variables 
and Mann-Whitney U-tests for non-parametric variables. Cat-
egorical variables in the form of baseline characteristics and 
proportions were compared using Pearson’s chi-squared test. 
The Cochran-Armitage trend test was used to test for trends in 
the proportions of patients using antithrombotics over time, in 
univariate analysis.
Relative risk (RR) estimates for the use of antithrombotics 
were calculated using multivariable Poisson regression with 
robust error variance, as described by Zou (2004). Analysis of 
time series data can be infl uenced by autocorrelation that affects 
the error terms, but not the estimates themselves. In the Poisson 
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regression, we therefore decided to use an autoregressive corre-
lation matrix specifi ed in the repeated statement in proc genmod 
in SAS. The model included the available variables—year, sex, 
age, and CCI—but not all known confounders.
2-sided p-values < 0.05 were considered signifi cant. Sta-
tistical analyses and data management were conducted using 
SAS version 9.3 through a secure remote connection provided 
by Statistics Denmark.
Ethics
According to Danish law, ethical committee approval is not 
required for this type of observational study. The data were 




154,047 patients were included, and 33% of them used 1 
or more antithrombotics on admission. Among the users of 
antithrombotics, there was a higher proportion of men and 
a higher mean age (Table 1). Furthermore, the users of anti-
thrombotics had a higher degree of comorbidity and a higher 
unadjusted 30-day mortality (all p < 0.001). Specifi c diseases 
for which antithrombotics are the treatment or part of it (for 
example, atrial fi brillation) were much more prevalent among 
users of antithrombotics.
Temporal trends in the use of antithrombotics—hip 
fracture patients
From 1996 to 2012, there was a 2.3-fold increase in the use of 
antithrombotics, a 6.8-fold increase in the use of anticoagu-
lants, and a 2.1-fold increase in the use of antiplatelet drugs 
(Figure 1 and Table 2). The 2 newer antiplatelet drugs ticagre-
lor and prasugrel are not included in the table due to the very 
low numbers of users. For ticagrelor, there was 1 user in 2011 
and 14 in 2012, and for prasugrel, 1 user in 2010.
In addition to the increase in the use of antithrombotics in 
general, there was also a statistically signifi cant increase in the 
number of patients using more than 1 antithrombotic (Figure 
2). From 1996 to 2012, there was a 54-fold increase in the 
proportion of patients using more than 1 antithrombotic and a 
16-fold increase in the proportion of patients using anticoagu-
lants and antiplatelet drugs concomitantly.
A multivariable Poisson regression analysis was conducted 
in order to determine what factors were associated with the 
use of antithrombotics, and to control for possible confounders 
(Table 3). There was an increase in relative risk regarding the 
use of both anticoagulants and antiplatelet drugs per annual 
increase in time since admission, even when controlling for 
confounding factors. Looking at other factors, there was an 
association between age, comorbidity (CCI), and gender, and 
increasing use of antithrombotics. 
Table 1. Baseline characteristics
 Users Non-users p-value
 n = 50,625 n = 103,422 
Female sex, n (%) 34,579 (68) 72,750 (70) < 0.001
Age in years, mean (SD) 81.5 (8.8) 76.7 (13.5) < 0.001 a
Charlson comorbidity index
 median (range) 1 (0–16) 0 (0–19) < 0.001 a
 n (%)
 0 13,025 (26) 59,613 (58) < 0.001
 1 12,847 (25) 19,615 (19)
 2 10,559 (21) 13,004 (13)
 ≥ 3 14,194 (28) 11,190 (11) 
Atrial fi brillation/fl utter, n (%) 10,251 (20) 3,743 (4) < 0.001
Ischemic heart disease, n (%)  14,632 (29) 6,127 (6) < 0.001
Valvular disease, n (%) 3,200 (6) 1,534 (2) < 0.001
Artifi cial heart valve, n (%) 619 (1) 111 (0) < 0.001
Stroke / TCI b, n (%) 4,206 (8 ) 1,546 (2) < 0.001
Arterial thromboembolism, n (%) 430 (1) 173 (0) < 0.001
Deep vein thrombosis, n (%) 1,746 (4) 1,537 (2) < 0.001
Pulmonary embolism, n (%) 909 (2) 494 (1) < 0.001
Fracture type, n (%)
 Femoral neck 30,027 (59) 60,880 (59)
 Pertrochanteric 17,512 (35) 35,378 (34)
 Subtrochanteric 3,086 (6) 7,164 (7) < 0.001
30-day mortality, n (%) 6,545 (13) 8,785 (9) < 0.001
a Mann-Whitney U-test. 
b TCI: transient cerebral ischemia.
Figure 1. Proportion of hip fracture patients who used antithrombotics, 1996 to 2012. Panel A shows the overall results, whereas panels B and C 
show the results for the individual anticoagulants and antiplatelet drugs, respectively. w/o ASA: without patients who used only acetylsalicylic acid.
* p-value for trend < 0.001.
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Temporal trends in the use of antithrombotics—the 
general population
To determine whether the trend observed in the hip fracture 
patients was comparable to the trend in the general population, 
we looked at the percentage of individuals in the general pop-
ulation (aged 18 years or more) who redeemed prescriptions 
for specifi c antithrombotics during the period 1999 to 2012. 
There was a statistically signifi cant increase in the number of 
subjects using antithrombotics from 1999 to 2012 (Table 4). 
Most of the hip fracture patients were 60 years old or more 
(> 91%), and the use of antithrombotics increased with age. 
Thus, we also looked at the use of antithrombotics in those 
aged 60 years or above in the general population. As this was 
only a crude comparison between hip fracture patients and the 
general population, no formal statistical analyses were used to 
compare the 2 populations.
Discussion
This study, covering the entire Danish population, shows for 
the fi rst time that there has been a substantial increase in the 
use of antithrombotics in hip fracture patients. The increase 
was seen for both anticoagulants and antiplatelet drugs.
The last 2 decades have seen the approval and marketing 
of several new antithrombotics, and their gradual uptake in 
patients is indicated by the results in Table 2. This includes 
drugs such as clopidogrel (which was approved in Denmark 
in 1998) and, most recently, the NOACs (which were fi rst 
approved in Denmark in 2008). In addition to these new drugs, 
there has also been an increase in the number of patients using 
older drugs such as aspirin and vitamin K antagonists. In com-
paring the data from the hip fracture patients with that from 
the general population, it is clear that the trends observed in 
hip fracture patients refl ect those seen in the general popula-
tion. The increase in the number of users of antithrombotics is 
in line with the results of studies showing increased use of, for 
example, anticoagulants for stroke prevention in atrial fi brilla-
tion (Karve et al. 2012, Shroff et al. 2014).
There appears to be a slight plateau in the number of users 
of antiplatelet drugs, and a continued increase in the number 
of patients using anticoagulants over the last 4–5 years. It is 
diffi cult to predict, however, how the use of antithrombotics 
will change in the future, but most interesting in this context 
is perhaps how the use of NOACs will change. This study 
only covered a limited length of time following approval and 
marketing of the fi rst NOAC in Denmark in 2008, and it was 
only in 2011 that NOACs were approved for atrial fribrillation 
in Denmark. It can be expected that there will be a marked 
Table 2. Temporal trends in the use of antithrombotics, 1996 to 2012
Drug 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 P for
n, % (11,399) (10059) (9681) (9697) (9426) (9464) (9253) (8901) (8976) (8949) (8598) (8612) (8607) (8208) (8479) (8079) (7659) trend
Any antithrom. 2,140 2,166 2,226 2,478 2,553 2,676 2,852 3,024 3,127 3,273 3,366 3,470 3,600 3,405 3,546 3,417 3,306
50,625, 32.9% 18.8% 21.5% 23.0% 25.6% 27.1% 28.3% 30.8% 34.0% 34.8% 36.6% 39.2% 40.3% 41.8% 41.5% 41.8% 42.3% 43.2% < 0.001
Any anticoag. 134 142 180 199 210 234 280 294 326 410 441 490 501 478 521 563 616
6,020, 3.9% 1.2% 1.4% 1.9% 2.1% 2.2% 2.5% 3.0% 3.3% 3.6% 4.6% 5.1% 5.7% 5.8% 5.8% 6.1% 7.0% 8.1% < 0.001
Vit. K ant. 134 142 180 199 210 234 280 294 326 410 441 490 501 478 520 558 567
5,964, 3.9% 1.2% 1.4% 1.9% 2.1% 2.2% 2.5% 3.0% 3.3% 3.6% 4.6% 5.1% 5.7% 5.8% 5.8% 6.1% 6.9% 7.4% < 0.001
NOAC - - - - - - - - - - - - 0 0 1 6 68
75, 0.1%               0.0% 0.1% 0.9% < 0.001
Any antiplat. 2,022 2,037 2,070 2,301 2,376 2,472 2,623 2,792 2,890 2,987 3,049 3,124 3,273 3,093 3,191 3,072 2,860
46,240, 30.0% 17.7% 20.3% 21.4% 23.7% 25.2% 26.1% 28.4% 31.4% 32.2% 33.4% 35.5% 36.3% 38.0% 37.7% 37.7% 38.0% 37.3% < 0.001
ASA 2,021 2,030 2,061 2,258 2,311 2,379 2,529 2,663 2,715 2,748 2,807 2,860 2,995 2,809 2,855 2,740 2,471 
43,259, 28.1% 17.7% 20.2% 21.3% 23.3% 24.5% 25.2% 27.3% 29.9% 30.3% 30.7% 32.7% 33.2% 34.8% 34.2% 33.7% 33.9% 32.3% < 0.001
Clopidogrel - - 0 1 5 21 33 67 98 129 113 128 190 189 221 308 396
1,899, 1.2%    0.0% 0.1% 0.2% 0.4% 0.8% 1.1% 1.4% 1.3% 1.5% 2.2% 2.3% 2.6% 3.8% 5.2% < 0.001
Dipyridamole 4 15 34 132 215 297 371 411 420 450 444 473 492 480 502 474 429
5,645, 3.7% 0.0% 0.2% 0.4% 1.4% 2.3% 3.1% 4.0% 4.6% 4.7% 5.0% 5.2% 5.5% 5.7% 5.9% 5.9% 5.9% 5.6% < 0.001
Combination - - - - - - 0 25 86 164 169 207 213 182 200 148 123
1,518, 1.0%         0.3% 1.0% 1.8% 2.0% 2.4% 2.5% 2.2% 2.4% 1.8% 1.6% < 0.001
The total number of hip fracture patients is shown under each year.
Antithrom: antithrombotics; Anticoag: anticoagulant; Vit. K. ant.: vitamin K antagonist; NOAC: new oral anticoagulants; antiplat.: antiplatelet; 
ASA: acetylsalicylic acid; Combination: combination antiplatelets; - : drug not marketed.
Figure 2. Proportion of hip fracture patients who used more than 1 
antithrombotic from 1996 to 2012. * p-value for trend < 0.001.
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increase in the number of patients using NOACs on admis-
sion in the years to come. This is supported by the fact that an 
increasing number of patients with atrial fribrillation in Den-
mark are now started on NOACs instead of warfarin (Olesen 
et al. 2015). The increasing use of NOACs could be a prob-
lem due to the lack of an antidote, and problems with reliable 
coagulation tests (Harder and Graff 2013). Furthermore, the 
use of NOACs can affect the choice of anesthesia, as neuraxial 
anesthesia will often be contraindicated in patients who are on 
NOACs (Benzon et al. 2013).
There is a consensus that surgery on hip fracture patients 
should be performed as soon as possible (Fernandez et al. 
2015). In this context, several studies have looked at the asso-
ciation between the use of antithrombotics on admission and 
outcome in hip fracture patients. In general, these studies have 
been of small scale, with few cases and a retrospective case-
control design. This is exemplifi ed by a recent systematic 
review and meta-analysis on early surgery in patients taking 
clopidogrel (Doleman and Moppett 2015). Pooling of all 
available studies with data on mortality yielded only 207 users 
of clopidogrel and 29 events (deaths) in that group. The study 
found that there was no increased risk of mortality in patients 
taking clopidogrel, but, as the authors indicated, the published 
studies have had shortcomings and additional studies are 
needed. The same is true for studies on vitamin K antagonists 
(Al-Rashid and Parker 2005, Collinge et al. 2012, Ahmed et 
al. 2014, Gleason et al. 2014).
Table 3. Multivariable analysis – factors associated with the use of antithrombotics
 Any antithrombotic Any anticoagulant Any antiplatelet
 RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value
Year (per year) a 1.03 (1.03–1.04) < 0.001 1.09 (1.09–1.10) < 0.001 1.03 (1.02–1.04) < 0.001
Gender (men) 1.13 (1.11–1.14) < 0.001 1.40 (1.34–1.46) < 0.001 1.11 (1.09–1.12) < 0.001
Age (per 10 years) 1.34 (1.33–1.35) < 0.001 1.14 (1.07–1.21) < 0.001 1.37 (1.35–1.38) < 0.001
CCI (per unit) 1.15 (1.14–1.16) < 0.001 1.18 (1.16–1.20) < 0.001 1.15 (1.15–1.16) < 0.001
The Poisson regression model included all 4 variables shown in the table.
a Calender year was included as a variable ranging from 0 to 16 (1996 = 0).
Table 4. Use of antithrombotics in the general Danish population in 1999 and 2012
 Age ≥ 18 years Age ≥ 60 years
 1999 a  2012  1999 a 2012
 (n = 4,180,601) (n = 4,378,227) p-value (n = 1,045,579) (n = 1,318,937) p-value
Vit. K ant. 1.0% (41,091) 2.1% (92,348) < 0.001   2.8% (29,373)   5.8% (75,889) < 0.001
NOAC 0.0% (248) 0.5% (20,177) < 0.001   0.0% (2)   0.2% (2,969) < 0.001
ASA 5.6% (232,128) 9.3% (408,286) < 0.001 18.6% (194,409) 25.4% (335,366) < 0.001
Clopidogrel 0.0% (1,615) 1.5% (64,549) < 0.001   0.1% (902)   3.9% (51,438) < 0.001
Dipyridamole 0.4% (15,607) 0.9% (39,495) < 0.001   1.2% (12,232)   2.6% (33,638) < 0.001
Combination 0.0% (323) 0.3% (13,018) < 0.001   0.0% (224)   0.8% (10,836) < 0.001
a For NOAC the fi rst year the drug was marketed was 2008, and for the combination antiplatelets it was 2002; the 
numbers indicated are from these years.
ASA: acetylsalicylic acid; Vit. K ant.: vitamin K antagonist; NOAC: new oral anticoagulants; Combination: combination 
antiplatelet drugs.
The low level of evidence in the studies on how to handle 
the use of antithrombotics in hip fracture patients at admission 
is also refl ected by the lack of consensus on which algorithms 
should be used in these patients (Inman et al. 2007, Palan et al. 
2007, Lavelle et al. 2008). There appears to be a need for clear 
evidence-based guidelines on the subject.
The limitations of our study were mainly related to the defi -
nition of use of the individual drugs. Use was defi ned as a 
minimum of 2 prescriptions redeemed within the last year, in 
order to only include chronic users. If a patient had just started 
taking the drug and had only redeemed 1 prescription, they 
would not have been classifi ed as users, leading to an underes-
timation of the number of users. 
Similarly, a patient could have stopped taking the medicine 
but still have redeemed 2 prescriptions within the last year, 
leading to an overestimation of the number of users. All in 
all, we believe that this was of minor importance—due to the 
large number of patients included and the likelihood of the 2 
scenarios balancing each other out. In addition, although the 
patients might actually have redeemed prescriptions for the 
drugs, we have no information on whether or not the patients 
actually took them.
The strengths of the study include the large number of 
patients, which covered all Danish hip fracture patients and 
the entire Danish population over a 17-year period. This per-
mitted a comprehensive analysis of temporal patterns in the 
use of even rarely used drugs. As the study covered an entire 
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population, this would also increase the generalizability of the 
results, and it is likely that the trends observed in the Danish 
population match those in other western countries. Another 
strength of the study was the use of the Danish national regis-
tries, which gave complete data on all prescriptions redeemed 
in Denmark at the individual level thanks to the civil registra-
tion number. The data were collected in an unbiased fashion 
from the registries, which contrasts with chart review.
An additional fi nding in our study was that the annual 
number of hip fractures appears to have decreased substan-
tially during the time frame investigated. This warrants further 
investigation in future studies.
In summary, the use of antithrombotics in hip fracture 
patients on admission increased substantially from 1996 to 
2012 in Denmark. This included the use of anticoagulants and 
antiplatelet drugs, and the combined use of the 2. These results 
highlight the need for evidence-based guidelines on how to 
handle patients taking antithrombotics on admission, in order 
to avoid surgical delay and ensure safe surgery.
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